Clay Siegall: Changing The Face Of Cancer

Mr. Siegall started his career many years ago after receiving his PhD in Genetics from George Washington University. Mr Siegall has a passion for helping those with cancer by researching for a cure. This commitment shows in his career choices. Clay started his career at the National Cancer Institute, National Institute of Health in 1988. Clay stayed in this position until 1991 when he was offered employment with the Bristol-Myers Squibb Pharmaceutical Research Institute. Mr. Siegall stayed at Bristol-Myers until 1997. At this time it was when Clay decided to start his own research facility, Seattle Genetics.

Seattle Genetics was founded in 1998 focusing on research and practical science to create advances in cancer eradication. Clay still serves as President, Chief Executive Officer, and Chairman of the Board. Seattle Genetics, under Clay’s leadership, has led the pharmaceutical market by creating antibody-drug conjugates (ADC’s). An ADC can target cancer cells and kill them from the inside out, leaving other non cancerous cells alone and causing less harm to the human body. With the discovery of ADC’s, Seattle Genetics has led the way for how cancer patients are treated.

Seattle Genetics has licensed the use of ADC’s to other pharmaceutical companies to fund further cancer treatment research. In addition to his duties for Seattle Genetics, Mr. Siegall shows his dedication to genetics research by serving on the board for Ultragenyx, Mirna Therapeutics, and Alder BioPharmaceuticals. Clay Siegall has been an innovative force in the field of cancer research, fundraising, and helping cancer patients find relief from traditional cancer treatment.

Seattle Genetics is a publicly traded company with over 800 employees all dedicated to the cure for cancer.

Leave a Reply

Your email address will not be published. Required fields are marked *